Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 148

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 148
---
 its favor and to endeavor to seek for its enforcement in Israel. In 2024, we initiated a proceeding in Germany to annul said German
court’s purported ruling. We submitted our arguments to the German court by way of a brief on April 11, 2025. In May 2025, the
German court issued a judgment dismissing our annulment claim. On July 4, 2025, we came to an agreement with CSL, or the CSL Settlement,
which would result in an immediate payment of $30,000 and a payment of $300,000 by us to CSL subsequent to the closing of this offering,
as well as reimbursement for certain of CSL’s legal expenses and two future payments of $300,000 and $200,000 by us to CSL upon
the achievement of certain global sales milestones.

Other than the proceeding
mentioned above, we are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business
face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including
intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these
claims could subject us to costly litigation and, while we generally believe that we have adequate insurance to cover many different
types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy
limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could
have a material adverse effect on our operations, cash flows and financial position. Additionally, any such claims, whether or not successful,
could damage our reputation and business.

<div align='center'>90

MANAGEMENT</div>

Executive Officers and Directors

The following table sets
forth information regarding our executive officers and directors, including their ages as of the date of this prospectus:

| Name                    |     | Age |     | Position                |
| Dr. Ehud Geller         |     |  78 |     | Director, Chairman      |
| Mr. Jeff Dykan          |     |  65 |     | Director                |
| Mr. Keith Valentine     |     |  56 |     | Director(1)             |
| Dr. Eli Hazum           |     |  76 |     | Chief Executive Officer |
| Mr. Arie ‌ Gord